Poging GOUD - Vrij
"India needs vaccines that are 'Made for India"
Bio Spectrum
|BioSpectrum India Jan 2025
With a legacy of over 75 years in pioneering advancements with their vaccines within the Indian pharmaceutical landscape, Mumbai-based Novo Medi Sciences (Novo Group) has been instrumental in introducing many first-of-itskind vaccines in India, playing a vital role in public health and setting standards in healthcare quality and accessibility.
-
The company is all set to launch new vaccines in the country, further strengthening the innovation landscape for vaccine R&D. Forum Bhagat, Managing Director of Novo Medi Sciences (Novo Group) spoke to BioSpectrum about the company's present and future plans. Edited excerpts:
What were the key highlights of the company in 2024? What are the major plans in store for 2025?
In 2024, we continued to expand our mission, considering that we must cater to critical healthcare challenges with innovative solutions. One of our recent key achievements, guided by the principles of our founder and my grandfather, late Ramesh C Bhagat, was the reintroduction of NEXICLOX DS 250mg, a trusted Cloxacillin syrup formulation.
This move addresses the dire need for effective treatments against critical infections like skin and soft tissue infections (SSTIs), osteomyelitis, respiratory tract infections (RTIs), and Endocarditis within the paediatric community. Initially launched in 1965, Cloxacillin is the gold-standard penicillin that was discontinued in the Indian pharmaceutical market for over 25 years. The rise of multi-drug resistance (MDR) has rendered many current combination molecules ineffective against susceptible Staphylococcus infections. Consequently, the medical fraternity emphasised the need for 'old is gold' standard molecules like Cloxacillin, which offers a lower likelihood of resistance due to its limited use in recent years.
By reintroducing NEXICLOX DS 250mg, we aim to provide healthcare professionals with a reliable and effective solution for treating critical infections in children, effective against MDR methicillin-susceptible Staphylococcus Aureus (MSSA) and has a low resistance risk with a proven safety profile.
Dit verhaal komt uit de BioSpectrum India Jan 2025-editie van Bio Spectrum.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Bio Spectrum
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.
3 mins
November 2025
Bio Spectrum
DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation
An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.
1 min
November 2025
Bio Spectrum
Abbott launches world's first dual-chamber leadless pacemaker system in India
Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.
1 min
November 2025
Bio Spectrum
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
November 2025
Listen
Translate
Change font size